Lithium carbonate 300 mg per capsule.
Pharmacology: Pharmacokinetics: Lithium alters sodium transport in nerve and muscle cells. It increases intraneuronal metabolism of catecholamines.
Lithium ions are readily absorbed when given orally. A plasma lithium peak is reached 2-4 hours after ingestion of lithium carbonate. Lithium is not bound to plasma proteins. The concentration in cerebrospinal fluid is only about half of that in plasma. The main route of excretion is through the kidneys.
Treatment of manic episodes of manic depressive illness.
Initially 300 mg (1 capsule) daily which may be gradually increased to 900 mg (3 capsules) in divided doses.
In manic depressive disease up to 1.8 gm (6 capsules) daily may be given.
The dosage must be adjusted to maintain plasma levels in the therapeutic ranges, which is between 0.5 and 1.5 mEq/L and careful observation is necessary for toxic effects.
Pregnancy & lactation. Severe cardiovascular or renal impairment, sodium depletion, hypothyroidism, addison's disease caution in concurrent administration of diuretics.
Fever, infections, mood swings. Regularly monitor serum concentrations. Elderly.
Contraindicated in pregnancy and lactation.
Nausea, vertigo, fine hand tremor, polyuria, muscle weakness, somnolence and lethargy, diarrhea, hyperparathyroidism with hypercalcaemia, leukocytosis, weight gain, edema, cardiac arrhythmias, exacerbation of skin conditions, impaired renal function, mild cognitive and memory impairment, hypothyroidism and/or goiter.
Concomitant use with sodium-containing medications, metronidazole, spectinomycin, tetracycline, carbamazepine, phenytoin, verapamil, mazindol, methyldopa, phenothiazines, haloperidol, NSAIDs, theophylline, antidepressants & diuretics.
N05AN01 - lithium ; Belongs to the class of lithium antipsychotics.
Sign Out
